Mineralys Therapeutics Earnings Call Transcripts
Fiscal Year 2026
-
Lorundrostat’s NDA was accepted in Q1, with robust clinical data supporting its use in resistant hypertension. Launch preparations are underway, focusing on key prescribers and payer engagement, while international commercialization will rely on partnerships. Cash reserves support operations into 2028.
-
FDA accepted the NDA for lorundrostat, supported by robust clinical data, with a PDUFA date set for December 2026. Cash reserves remain strong, and operational focus is on commercial launch readiness and strategic partnerships. Significant market opportunity exists in resistant hypertension.
Fiscal Year 2025
-
FDA accepted the NDA for lorundrostat, setting a PDUFA date of December 22, 2026. Strong clinical results and a robust cash position support launch preparations, with ongoing payer engagement and expanded medical communications. Net loss narrowed year-over-year as R&D spending declined.
-
Significant clinical progress was highlighted, with NDA submission for lorundrostat expected by early 2025 and launch targeted for late 2026 to early 2027. Commercial readiness is strong, with a focus on efficient market entry and ongoing partner discussions.
-
Lorundrostat has shown robust, best-in-class efficacy and safety in resistant and uncontrolled hypertension, with strong data across diverse populations and a favorable comparison to competitors. Market entry will focus on high-need patients, with expansion supported by ongoing studies and a flexible commercialization approach.
-
Hypertension remains a major unmet need, with lorundrostat and the ASI class offering significant innovation by targeting dysregulated aldosterone. Clinical data show robust BP reductions and a favorable safety profile, with a large U.S. market opportunity and regulatory filings expected soon.
-
Lorundrostat showed strong, sustained BP reductions in diverse, high-risk populations, with NDA submission expected by early 2026. Financials improved with a lower net loss and a strong cash position to fund operations into 2028. Commercial and partnering strategies are advancing.
-
Lorundrostat is advancing toward FDA submission following strong pivotal data in hypertension, with additional trials in CKD and OSA supporting broader use. Initial commercialization will target fourth-line patients, with plans to expand and ongoing partnership discussions to maximize reach.
-
Lorundrostat showed strong efficacy and safety in pivotal hypertension and CKD trials, with high physician interest and a robust financial position supporting operations into 2027. Regulatory milestones are on track, and market research indicates significant unmet need and commercial potential.
-
Explorer-CKD phase 2 trial showed lorundrostat 25 mg daily significantly reduced systolic blood pressure and albuminuria in CKD patients with uncontrolled hypertension, with a favorable safety profile and manageable hyperkalemia. These results support its use as an add-on therapy and will be included in the upcoming NDA submission.
-
Significant blood pressure reductions were achieved in two pivotal studies of lorundrostat, with robust efficacy and a favorable safety profile across diverse patient groups. Ongoing studies in CKD and OSA will further define its potential, and a pre-NDA meeting is planned for Q4.
-
Positive pivotal trial results for lorundrostat in hypertension showed strong efficacy and safety, with high physician interest and robust financials supported by a $201.2 million equity raise. NDA submission is planned following a pre-NDA FDA meeting in Q4 2025.
-
Lorundrostat demonstrated robust and consistent blood pressure reductions with a favorable safety profile in pivotal trials, addressing a major unmet need in resistant hypertension. Physician and payer feedback indicate strong market potential for third- and fourth-line use.
-
Two pivotal phase III trials demonstrated that lorundrostat significantly reduced systolic blood pressure in uncontrolled and resistant hypertension, with a strong safety and tolerability profile. The 50 mg dose was optimal, and efficacy was consistent across diverse patient groups.
Fiscal Year 2024
-
Pivotal hypertension trials Advance-HTN and Launch-HTN are on track for major data readouts in early 2025, with strong financial resources to support operations through Q1 2026. Lorundrostat's clinical profile and market positioning are expected to address significant unmet needs in resistant hypertension.
-
Upcoming pivotal hypertension trials are designed for robust efficacy and safety, with all patients on diuretics and titration strategies to optimize response. Key data readouts are expected in the first half of 2025, and current cash reserves are sufficient to fund all planned studies.
-
The conference highlighted advances in diagnosing and treating aldosterone-driven hypertension, with pivotal trials designed to address both specialist and real-world populations. Lorundrostat demonstrated strong efficacy and safety, with upcoming studies focusing on obesity, resistance, and CKD benefits.
-
Lorundrostat is advancing through two pivotal hypertension trials, targeting patients with resistant or obesity-related hypertension. The studies are designed for both specialist and real-world settings, with robust compliance and diversity. Data readouts are expected in early 2025.
-
Enrollment completed in two pivotal hypertension trials for lorundrostat, with top-line data expected in early 2025. Cash reserves of $263.6 million support operations into 2026, despite increased R&D spending and a higher net loss.
-
Hypertension remains poorly controlled, with resistant cases often linked to excess aldosterone. Lorundrostat, a selective aldosterone synthase inhibitor, has shown promising blood pressure reductions, especially in obese and high-risk populations. Two pivotal trials are fully enrolled, with results expected in 2025.
-
Mineralys is advancing lorundrostat, a selective aldosterone synthase inhibitor, through rigorous clinical trials targeting hypertension and CKD. The company is well-funded, expects pivotal data in 2025, and is positioned to address significant unmet needs in cardiorenal diseases.
-
Lorundrostat clinical trials advanced, with pivotal hypertension studies nearing completion and a CKD trial progressing after protocol amendments. Cash reserves support operations into 2026, while R&D expenses rose sharply due to increased clinical activity.
-
Upcoming pivotal study readouts for lorundrostat in hypertension are expected to validate its targeted approach for aldosterone-driven cases, with design changes enhancing statistical power and regulatory alignment. The company is also advancing a CKD program and exploring commercial partnerships.